Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Evolus, Inc. - Common Stock (NQ: EOLS )

11.75 +0.20 (+1.73%)
Streaming Delayed Price Updated: 1:42 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Evolus, Inc. - Common Stock

< Previous 1 2 3 4 Next >
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Breaking Down Evolus: 8 Analysts Share Their Views
Via Benzinga
Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas
There's a lot going on for investors. 
Via The Motley Fool
Assessing Evolus: Insights From 6 Financial Analysts
Via Benzinga
Breaking Down Evolus: 4 Analysts Share Their Views
Via Benzinga
4 Analysts Have This To Say About Evolus
Via Benzinga
A Closer Look at 5 Analyst Recommendations For Evolus
Via Benzinga
Analyst Scoreboard: 4 Ratings For Evolus
Via Benzinga
Evolus: Chiseling Away At The Aesthetic Market
Via Talk Markets
Earnings Scheduled For March 4, 2025
Via Benzinga
Nasdaq Jumps 100 Points; Charles Schwab Profit Beats Estimates
Via Benzinga
Recap: Evolus Q4 Earnings
Via Benzinga
Earnings Outlook For Evolus
Via Benzinga
AbbVie Stock Clears Key Benchmark, Hitting 80-Plus RS Rating
A Relative Strength Rating upgrade for AbbVie shows improving technical performance. 
Via Investor's Business Daily
Crude Oil Down 2%; D.R. Horton Earnings Top Views
Via Benzinga
Exposures Fossil Fuels
Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere — Here's Why
The company expects to soon expand from a single-product player to a "multi-product innovator." 
Via Investor's Business Daily
Charles Schwab Posts Upbeat Earnings, Joins Redwire, Evolus, Replimune Group And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q2 2024
EOLS stock results show that Evolus missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters Early
The company reported $1.1 million in adjusted operating income, well ahead of expectations for a $2.6 million loss. 
Via Investor's Business Daily
EOLS Stock Earnings: Evolus Beats EPS, Beats Revenue for Q1 2024
EOLS stock results show that Evolus beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are worth checking out with our coverage of all the latest and greatest news happening on Thursday! 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q4 2023
EOLS stock results show that Evolus missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Novo Nordisk Stock Just Earned A 92 RS Rating; Gapped Up On Earnings
Novo Nordisk ADR sees its Relative Strength Rating move into the elite 90-plus level. 
Via Investor's Business Daily
Earnings Scheduled For March 7, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. 
Via Benzinga
Why Panbela Therapeutics Shares Are Trading Lower By 65%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Panbela Therapeutics, Inc. (NASDAQ: PBLA) fell sharply during Monday’s session after the company announced pricing of a roughly $9 million public offering. Panbela Therapeutics shares dipped... 
Via Benzinga
SoFi Technologies Posts Q4 Earnings, Joins Cardlytics, McGrath RentCorp And Other Big Stocks Moving Higher On Monday
U.S. stocks traded mixed, with the Dow Jones trading slightly lower on Monday. Shares of SoFi Technologies, Inc. (NASDAQ: SOFI) rose sharply during Monday’s session after the company reported... 
Via Benzinga
Topics Stocks
Exposures US Equities
Evolus Set For Promising 2024: Analysts Maintain Positive Outlook On Botox Alternative Maker
Evolus beats Q4 revenue expectations, up 40% YoY at $61M. Full-year 2023 hits $202M, exceeding guidance. Analysts bullish on Evolus. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Aesthetics Market Resilience: AbbVie Asserts Widely Used Botox Dominance Amidst Rising Competition
AbbVie Inc's (NYSE: ABBV) unwavering confidence in Botox's resilience within the aesthetics market with a commanding 68% market share remains steadfast. Despite a recent FDA petition addressing... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.